Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus nivolumab in second-line stage IV non-small cell lung cancer with bone metastases
2018-001105-85Phase 2Completed
- Sponsor
- Centre Hospitalier Annecy Genevois
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by Centre Hospitalier Annecy Genevois. Primary endpoint: Objective response rate according to PD-L1 expression. Started Apr 2018; status: completed.
02
Drugs
denosumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001105-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001105-85.